HCPLive has posted a new expert segment focused on real-world risankizumab durability in high-impact psoriasis. Tina Bhutani, MD, MAS, leads the discussion, and the conversation targets the question clinicians ask most often once a patient has cleared on the IL-23 inhibitor: how long does the drug actually hold up outside trial walls?

That is the practical bridge real-world data builds. Pivotal studies recruit selected patients under controlled follow-up and report on-response endpoints at fixed intervals. Routine practice treats a broader mix — older adults, biologic-experienced patients, those with comorbid psoriatic arthritis, and the patients whose disease lives in sites that standard PASI scoring under-captures. For those patients, persistence on drug, not the percentage cleared at week 16, carries the weight.

Bhutani's segment focuses the durability conversation on high-impact psoriasis, a clinical category defined by plaque disease at the sites where conventional body-surface scoring flattens the lived experience. The scalp. Nails. Palms and soles. Genitalia. Clearance at these sites is slow on most agents; relapse is functionally meaningful in ways a PASI number does not register. That is why durability data is more clinically actionable here than anywhere else on the body.

Why does this matter at the prescription pad?

Three operations downstream of the durability signal.

• Drug selection. Choosing a first-line IL-23 inhibitor now leans harder on expected real-world persistence than on incremental differences in pivotal PASI response. Two agents with similar trial efficacy curves can carry meaningfully different community retention profiles, and that gap drives total time on therapy before any switch.
• Patient counseling. Newly started patients in shared decision-making visits expect a credible answer to how long will this last. Real-world durability data is the closest evidence base a prescriber can offer.
• Access documentation. Prior-authorization reviews increasingly ask which high-impact-site outcomes were tracked. The records that move a step-up request through review are the records the practice has to keep.

What's in the HCPLive segment?

The piece walks through why real-world discontinuation curves typically run steeper than pivotal follow-up retention, how prior biologic exposure shifts the picture, and what the available persistence data suggests for community practice. Bhutani addresses the durability signal across the high-impact sites and the implications for switching decisions in biologic-experienced patients.

Practitioners should watch the full segment for the specific persistence figures, the cohort definitions behind the real-world data, and the patient-quotable framing offered for shared decision-making visits.

What does it change for community prescribers?

Track persistence on risankizumab in your own biologic-experienced and high-impact-site patients. Compare that local curve against the published real-world data. Use the comparison in subsequent prior-authorization documentation. Real-world durability is the metric that survives contact with formulary committees, and the metric prescribers need in hand is the one they generate themselves.

Expect further risankizumab and IL-23 inhibitor real-world evidence over the next 12 to 18 months as community prescriptions cross multi-year follow-up and as head-to-head real-world comparisons mature into the published record. That next wave will convert trial-era durability claims into the practice-grounded persistence numbers that determine access at the formulary level.